- RecruitingPHASE3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
This study looks at combining two medicines, vedolizumab and upadacitinib, for adults with moderate to severe Crohn's Disease. It aims to see if this combination better reduces bowel inflammation and ulcers compared to vedolizumab alone, and to check its safety.
For: Crohn's DiseaseUnited States · Austria · Belgium - RecruitingPHASE4
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
This study looks at new ways to treat Crohn's disease using a gentle scan called intestinal ultrasound. It aims to see if targeting 'transmural healing' – healing all layers of the bowel wall – alongside other measures, works better than standard care for people with moderately to severely active Crohn's.
For: Moderately to Severely Active Crohn's Disease · Crohn Disease · Disease CrohnUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
This study compares two approved medicines, risankizumab and vedolizumab, for adults with moderate to severe ulcerative colitis who haven't tried similar treatments before. It looks at how safe and effective they are. Around 530 people will take part worldwide.
For: Ulcerative ColitisUnited States · Austria · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE)
This study compares a new medicine (PB016) with an existing one (Entyvio®) for adults with moderate to severe ulcerative colitis. It looks at how well they work to reduce symptoms and keep people well, as well as their safety.
For: ulcerative colitisCzechia · Poland · Romania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis
This study is comparing two medicines, AVT16 and Entyvio, for people aged 18-80 with moderate to severe ulcerative colitis. It will check how well they work, how safe they are, and how the body reacts to them over 52 weeks. The main goal is to see if symptoms improve after 6 weeks.
For: Moderate to Severe Active Ulcerative ColitisCroatia · Latvia · Slovakia